2.Cosgrove, SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42(Suppl 2):S82–S89.
3.Maragakis, LL, Perencevich, EN, Cosgrove, SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008;6:751–763.
4.Shorr, AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009;37:1463–1469.
5.European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2011. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Control and Prvention, 2012.
6.Molton, JS, Tambyah, PA, Ang, BS, Ling, ML, Fisher, DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis 2013;56:1310–1318.
7.Master, RN, Deane, J, Opiela, C, Sahm, DF. Recent trends in resistance to cell envelope-active antibacterial agents among key bacterial pathogens. Ann N Y Acad Sci 2013;1277:1–7.
8.Stelling, JM, Travers, K, Jones, RN, Turner, PJ, O'Brien, TF, Levy, SB. Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg Infect Dis 2005;11:873–882.
9.Sannes, MR, Kuskowski, MA, Johnson, JR. Geographical distribution of antimicrobial resistance among Escherichia coli causing acute uncomplicated pyelonephritis in the United States. FEMS Immunol Med Microbiol 2004;42:213–218.
10.Zilberberg, MD, Shorr, AF, Kollef, MH. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000–2005. Emerg Infect Dis 2008;14:1756–1758.
11.Zhanel, GG, DeCorby, M, Adam, H, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother 2010;54:4684–4693.
12.Kallen, AJ, Hidron, AI, Patel, J, Srinivasan, A. Multidrug resistance among Gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008. Infect Control Hosp Epidemiol 2010;31:528–531.
13.Gales, AC, Jones, RN, Sader, HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 2011;66:2070–2074.
14.Diekema, DJ, Pfaller, MA, Schmitz, FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001;32(Suppl 2):S114–S132.
16.Siegel., JD, Rhinehart., E, Jackson., M, Chiarello., L. Committee. tHICPA. Management of multidrug-resistant organisms in healthcare settings, 2006. Centers for Disease Control and Prevention website. http://www.cdc.gov/hicpac/pdf/MDRO/MDROGuideline2006.pdf. Published 2006. Accessed February 3, 2014. 17.Smith, DL, Dushoff, J, Perencevich, EN, Harris, AD, Levin, SA. Persistent colonization and the spread of antibiotic resistance in nosocomial pathogens: Resistance is a regional problem. Proc Soc Natl Acad Sci USA 2004;101:5696–5696.
18.Schwaber, MJ, Lev, B, Israeli, A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli Hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52:848–855.
19.Won, SY, Munoz-Price, LS, Lolans, K, et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011;53:532–540.
20.Wisconsin Division of Public Health. Guidance for preventing transmission of carbapenem-resistant Enterobacteriaceae (CRE) in acute care and long-term care hospitals. Wisconsin Division of Public Health website. http://www.dhs.wisconsin.gov/publications/P0/p00532A.pdf. Published 2014. Accessed February 3, 2014. 24.U.S. Government Accountability Office. Antibiotic Resistance: Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring. GAO-11-406, 2011. Washington D.C. Government Accountability Office website. http://www.gao.gov/assets/320/319110.pdf. Published 2011. Accessed February 3, 2014. 26.Rothman, KJ, Boice, JDJ. Epidemiologic analysis with a programmable calculator. NIH Pub No. 79-1649. Bethesda, MD: National Institutes of Health, 1979.
27.Graubard, BI, Korn, EL. Predictive margins with survey data. Biometrics 1999;55:652–659.
28.Wolter, KM. Introduction to Variance Estimation. 2nd ed. New York, NY: Springer, 2007.
29.Tillotson, GS, Draghi, DC, Sahm, DF, Tomfohrde, KM, del Fabro, T, Critchley, IA. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005–07: laboratory-based surveillance study. J Antimicrob Chemother 2008;62:109–115.
30.Hennekens, CH, Buring, JE, Mayrent, SL. Epidemiology in Medicine. Boston, MA: Little, Brown and Co, 1987.
31.Kuster, SP, Ruef, C, Bollinger, AK, et al. Correlation between case mix index and antibiotic use in hospitals. J Antimicrob Chemother Oct 2008;62:837–842.
32.Magill, SS, Edwards, JR, Bamberg, W, et al. Multi-state point prevalence survey and national burden of healthcare-associated infections. N Engl J Med 2014;370:1198–1208.
33.Schwaber, MJ, De-Medina, T, Carmeli, Y. Epidemiological interpretation of antibiotic resistance studies—what are we missing? Nature Rev Microbiol 2004;2:979–983.